Mecasermin

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mecasermin
Clinical data
Trade namesIncrelex
SynonymsFK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life5.8 hours[1]
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC331H512N94O101S7
Molar mass7648.67 g/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[1][2][3]

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[1]

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[4] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[4]

References[edit]

  1. ^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021839s016lbl.pdf
  2. ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and Clinical Risk Management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
  3. ^ "Increlex". Drugs.com. Retrieved 10 January 2010.
  4. ^ a b https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021884s001lbl.pdf